Противовирусная и антикоагулянтная терапия у полиморбидного пациента с хроническим вирусным гепатитом С. Тактика ведения, особенности межлекарственных взаимодействий

Автор: Воловникова В.А., Зиновьева Е.Н.

Статья в выпуске: 10, 2018 года.

Бесплатный доступ

В статье изложены современные подходы к лечению хронического вирусного гепатита С генотипа 3, проанализирована обоснованность применения антикоагулянтов при заболеваниях печени, изложены принципы применения антикоагулянтной терапии у пациентов с протезированными клапанами и ее особенности при проведении противовирусной терапии с использованием ингибиторов протеаз, рассмотрены особенности межлекарственных взаимодействий и тактика ведения полиморбидного пациента, а также особенности оценки выраженности печеночной дисфункции и прогноза при хронических заболеваниях печени и циррозах у пациентов, получающих лечение антагонистом витамина К. Представлен клинический случай применения комбинированной противовирусной терапии у пациентки с механическим протезом митрального клапана, получающей постоянную терапию антагонистами витамина К.

Еще

Хронический вирусный гепатит с, противовирусная терапия, ингибиторы протеаз, антикоагулянты, антагонисты витамина к, протезированные клапаны сердца, коморбидный больной

Короткий адрес: https://sciup.org/14113433

IDR: 14113433 | DOI: 10.32415/jscientia.2018.10.02

Список литературы Противовирусная и антикоагулянтная терапия у полиморбидного пациента с хроническим вирусным гепатитом С. Тактика ведения, особенности межлекарственных взаимодействий

Lavanchy D. Evolving epidemiology of hepatitis C virus//Clin. Microbiol. Infect. 2011. Vol.17. Pp. 107-115.
Leebeek F.W, Kluft C, Knot E.A., de Maat M.P., Wilson J.H. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis//Gastroenterology. 1991. Vol. 101. Pp. 1382-1390.
De Carolis D.D., Westanmo A.D., Chen Y.C. et al. Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin//Ann. Pharmacother. 2016. Vol. 50(11). Pp. 909-917.
Britnell S.R., Willets A.E., Vanderman A.J., Woodard C.L., Britt R.B. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans//Pharmacotherapy. 2016. Vol. 36(11). Pp. 1173-1179.
Chevaliez S., Feld J., Cheng K., Wedemeyer H., Sarrazin C., Maasoumy B., et al. Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen//Antivir. Ther. 2016. .
Chevaliez S., Soulier A., Poiteau L., Bouvier-Alias M., Pawlotsky J.M. Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C//J. Clin. Virol.2014. Vol.61. Pp. 145-148.
EASL Recommendations on Treatment of Hepatitis C 2015//Journal of Hepatology. 2015. Vol. 63. Pp. 199-236.
Lawitz E., Sulkowski M.S., Ghalib R., Rodriguez-Torres M., Younossi Z.M., Corregidor A. et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study//Lancet. 2014. Vol. 384. Pp. 1756-1765.
Doab A., Treloar C., Dore G.J. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia//Clin. Infect. Dis. 2005. Vol. 40. Pp. 313-320.
Jensen D.M., O’Leary J.G., Pockros P.J., Sherman K.E., Kwo PY., Mailliard M.E., et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort//Hepatology. 2014. Vol. 60. Pp. 219A.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection//J. Hepatol. 2011. Vol. 55. Pp. 245-264.
Lawitz E., Poordad F., Brainard D.M., Hyland R.H., An D., Symonds W.T. et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study//Hepatology. 2013. Vol. 58. Pp. 1380A
Esteban R., Nyberg L., Lalezari J., Ni L., Doehle B., Kanwar B. et al. Successful retreatment with sofosbuvir-containing regimens for HCV genotype 2 or 3 infected patients who failed prior sofosbuvir plus ribavirin therapy//J. Hepatol. 2014. Vol. 60. P. 4
Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon SC. et al. Sofosbuvir for previously untreated chronic hepatitis C infection//N. Engl. J. Med. 2013. Vol. 368:. Pp. 1878-1887.
Jacobson I.M., Gordon S.C., Kowdley K.V., Yoshida E.M., Rodriguez-Torres M., Sulkowski M.S. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options//N. Engl. J. Med. 2013. Vol. 368. Pp. 1867-1877.
Zeuzem S., Dusheiko G.M., Salupere R., Mangia A., Flisiak R., Hyland R.H. et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3//Gastroenterology. 2014. Vol. 370. Pp. 1993-2001.
Sulkowski M.S., Gardiner D.F., Rodriguez-Torres M., Reddy K.R., Hassanein T., Jacobson I. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection//N. Engl. J. Med. 2014. Vol. 370. Pp. 211-221.
Nelson D.R., Cooper J.N., Lalezari J.P, Lawitz E., Pockros P.J., Gitlin N. et al. Alloral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study//Hepatology. 2015. Vol. 61. Pp. 1127-1135.
EASL Recommendations on Treatment of Hepatitis C 2016//J. of Hepatology. 2017. Vol. 66. Pp. 153-194.
EASL Recommendations on Treatment of Hepatitis C 2018//J. of Hepatology. 2018. Vol. 69.Pp. 461-511.
Butchart E.G., Gohlke-Barwolf C., Antunes M.J., Tornos P., De CaterinaR. et al. Working Groups on Valvular Heart Disease, Thrombosis, and Cardiac Rehabilitation and Exercise Physiology, European Society of Cardiology. Recommendations for the management of patients after heart valve surgery//Eur. Heart. J. 2005. Vol. 26:2. Pp. 463-2471.
Rivas-Gandara N., Ferreira-Gonzalez I., Tornos P., Torrents A., Permanyer-Miralda G. et al. Enoxaparin as bridging anticoagulant treatment in cardiac surgery//Heart. 2008. Vol. 94. Pp. 205-210.
Meurin P., Tabet J.Y., Weber H., Renaud N., Ben Driss A. Low-molecular-weight heparin as a bridging anticoagulant early after mechanical heart valve replacement//Circulation. 2006. Vol. 113 Pp. 564-569.
Kristensen S.D., Knuuti J., Saraste A., Anker S., Botker H.E. et al. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and anagement: the Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)//Eur. Heart J. 2014. Vol. 35. Pp. 2383-2431.
Iung B., Rodes-Cabau J. The optimal management of anti-thrombotic therapy after valve replacement: certainties and uncertainties//Eur. Heart J. 2014. Vol. 35. Pp. 2942-2949.
Brennan J.M., Edwards F.H., Zhao Y., O’Brien S., Booth M.E., Dokholyan R.S, Douglas P.S., Peterson E.D., DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database//J. Am. Coll. Cardiol. 2012. Vol. 60. Pp. 971-977.
Merie C., Kober L., Skov Olsen P., Andersson C., Gislason G., Skov Jensen J., Torp-Pedersen C. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding//JAMA. 2012. Vol. 308. Pp. 2118-2125.
Дземешкевич С.Л., Панченко Е.П. Антикоагулянтная терапия у пациентов с клапанными пороками сердца//РМЖ. 2001. T.9. №10. C. 427-430.
Heidbuchel H., Verhamme P., Alings M., Antz M., Diener H.C., Hacke W., Oldgren J., Sinnaeve P., Camm A.J., Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation//Europace. 2015. Vol. 17. Pp. 1467-1507.
Cannegieter S.C., Rosendaal F.R., Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses//Circulation. 1994. Vol. 89. Pp. 635-641.
Mok C.K., Boey J., Wang R., Chan T.K., Cheung K.L., Lee P.K., Chow J., Ng R.P., Tse T.F. Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial//Circulation. 1985. Vol. 72. Pp. 1059-1063.
Hart R.G., Benavente О., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a metaanalysis//Ann. Intern. Med. 1999. Vol. 131. Pp. 492-501.
Torella M., Torella D., Chiodini P., Franciulli M., Romano G. et al. LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial//Am. Heart. J. 2010. Vol. 160. Pp. 171-178.
Puskas J., Gerdisch M., Nichols D. et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial//J. Thorac. Cardiovasc. Surg. 2014. Vol. 147. Pp. 1202-1210; discussion 1210-1201.
Tripodi A., Mannucci P.M. The coagulopathy of chronic liver disease//N. Engl. J. Med. 2011. Vol. 365. P.147-156.
Francoz C., Belghiti J., Vilgrain V. et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation//Gut. 2005. Vol. 54. Pp. 691-697.
Abdel-Razik A., Mousa N., Elhelaly R., Tawfik A. De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system//Eur. J. Gastroenterol. Hepatol. 2015. Vol. 27. Pp. 585-592.
Loffredo L., Pastori D., Farcomeni A., Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis//Gastroenterology. 2017 Aug;153(2):480-487.e1.
Goriacko P., Veltri K.T. Safety of Direct Oral Anticoagulants versus Warfarin in Patients with Chronic Liver Disease and Atrial Fibrillation//Eur. J. Haematol. 2018. Feb 14.
Turon F., Hernández-Gea V., García-Pagán J.C. Portal vein thrombosis: yes or no on anticoagulation therapy//BMJ C.e Rep. 2018 Jan 12;2018. pii: bcr-2017-223479.
Hum J., Shatzel J.J., Jou J.H, Deloughery T.G., Dig Dis Sci. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis//Eur. J. Haematol. 2017 Apr. Vol. 98(4). Pp. 33-397
Intagliata N.M., Henry Z.H., Maitland H., et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation//Curr. Treat. Options. Gastroenterol. 2016 Jun. Vol. 14(2). Pp. 247-56.
Leonardi F., Maria N., Villa E. Anticoagulation in cirrhosis: a new paradigm?//Clin. Mol. Hepatol. 2017 Mar. Vol. 23(1). Pp. 13-21.
Burroughs A.K. et al. Anticoagulation after liver transplantation: a retrospective audit and case-control study//Blood. Coagul. Fibrinolysis. 2009. Vol. 8 (20). Pp. 615-618.
Vilaseca M, García-Calderó H, et al. The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells//Hepatology. 2017 Jun. Vol.65(6). Pp. 2031-2044.
Fortea J.I., Zipprich A., Fernandez-Mena C. et al. Enoxaparin does not ameliorate Liver fibrosis or portal hypertension in rats with advanced cirrhosis//Liver. Int. 2018 Jan. Vol. 38(1). Pp. 102-112.
Tripodi A., D'Ambrosio R., Padovan L. et al. Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis//Liver Int. 2017 Sep. Vol. 37(9). Pp. 1295-1303.
Mohamed M.S., Hanafy A.S., Bassiony M.A.A., Hussein S. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients. Expert Rev Gastroenterol Hepatol.//Eur. J. Gastroenterol. Hepatol. 2017 Dec. Vol. 29(12). Pp. 1368-1372.
Elsharkawy A., Eletreby R., Fouad R. et al. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients//Expert. Rev. Gastroenterol. Hepatol. 2017 Aug. Vol. 11(8). Pp. 773-778.
Wiegand J., Schiefke I., Stein K. et al. Interferon-free treatment of chronic hepatitis C virus infection in patients with inherited bleeding disorders//Hamostaseologie. 2017 May 10. Vol. 37(2). Pp. 127-130.
Miyashima Y., Honma Y., Miyagawa K. et al. Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions//Intern. Med. 2016. Vol. 55(24). Pp. 3595-3601.
Puglisi G.M., Smith S.M., Jankovich R.D., Ashby C.R. Jr, Jodlowski TZ. Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report//J. Clin. Pharm. Ther. 2017 Feb. Vol. 42(1). Pp. 115-118.
Schulman S. Inhibition of warfarin activity by ribavirin//Ann. Pharmacother. 2002 Jan. Vol. 36(1). Pp.72-74.
Badri PS, Dutta S, Wang H et al. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir//Antimicrob. Agents Chemother. 2015 Oct 12. Vol. 60(1). Pp. 105-114.
Pugh R.N.H., Murray-Lyon I.M., Danson J.L. Transection of the oesophagus for bleeding oesophageal varices//Brit. J. Surg. 1973. Vol. 8 (60). Pp. 646-648.
Flodén A Calculation and comparison of the model for end-stage liver disease (MELD) score in patients accepted for liver transplantation in 1999 and 2004//Transplant. Proc. 2007. Vol.39. Pp. 385-386.
Porte R.J., Lisman T., Tripodi A., Caldwell S.H., Trotter J.F. Coagulation in Liver Disease Study Group: The international normalized ratio (INR) in the MELD score: problems and solutions//Am. J.Transplant. 2010. Vol. 10. P.1349-1353.
Lisman T., van Leeuwen Y., Adelmeijer J. et al. Interlaboratory variability in assessment of the model of end-stage liver disease score//Liver Int. 2008. Vol. 28. Pp. 1344-1351.
Tripodi A., Chantarangkul V., Primignani M. et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation//Hepatology. 2007. Vol. 46. Pp. 520-527.
Lisman T., Porte R.J. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences//Blood. 2010. Vol. 116. Pp. 878-885.
Tripodi A., Baglin T., Robert A. et al. Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis: Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease//J. Thromb. Haemost. 2010. Vol. 8. Pp. 1410-1412.
Dabbagh O., Oza A., Prakash S., Sunna R., Saettele T.M. Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease//Chest. 2010. Vol. 137. Pp. 1145-1149.
Anthony Lizarraga W., Dalia S., Reinert S.E., Schiffman F.J. Venous thrombosis in patients with chronic liver disease//Blood Coagul. Fibrinolysis. 2010. Vol. 21. Pp. 431-435.
Levi M., Hovingh G.K., Cannegieter S.C., Vermeulen M., Büller H.R., Rosendaal F.R. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based//Blood. 2008. Vol. 111. Pp. 4471-4476.

Еще

Статья научная